Clinical Trial Search

Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants

Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate

Primary: Number and Percentage of Patients Achieving Virologic Resuppression — 256; 263 Participants

Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35

Primary: Treatment Response at Week 48 — 33.80; 16.20 percentage of participants — p=0.0001

Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score

Primary: Daily Change in log10 Colony-forming Unit (CFU) — -0.06; -0.18; -0.21; -0.15 log10 CFU per mL sputum per day

Primary: Proportion of Participants With Treatment Failure — 0.0682; 0.0667 proportion of participants

Primary: Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment — 41; 40; 41; 37 Participants

Primary: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF — 0.825 proportion of participants

Primary: Time to Sputum Culture Conversion — 5.9; 6.3; 6.1; 6.1 weeks

Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21

Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants

Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05

Primary: Medication Adherence as Assessed by the Medication Event Monitoring System (MEMS) Cap — 52.2; 27.2 percentage of participants

Primary: Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks — 0.64; 0.44; 0.88; 0.88 proportion of participants

Primary: Proportion of Patients With Sterile Sputum Cultures — 59; 45 Participants

Primary: Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment — 26.0; 29.8…

Primary: Mean Change From Baseline in QTcF — 12.3; 8.6; 20.7 milliseconds (ms)

Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026

Primary: Antimicrobial Resistance (AMR) of Conjunctiva at 1 Week — 0; 0; 0 reads per million reads — p=1

Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml

Primary: All-cause Mortality (1-59 Months Old) — 13.8; 11.9; 13.9 deaths per 1,000 person-years

Primary: Number of Patients Converted to Sputum Culture Negative in Each Arm, With Data Censored at 4 Months. — 15; 7 participants

Primary: Number of Participants With New or Recurrent AIDS Event, or Death — 83; 82 participants — p=0.69

Primary: Days of Antibiotic Therapy Per 1000 Days of Care — 710; 744 Days of Antibiotic Therapy/1000 Bed Days

Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants

Primary: Treatment Response at Week 48 — 34.5; 15 percentage of participants — p=0.0001

Primary: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) — 38…

Primary: Time to 26 Weeks Stable Culture Conversion in Liquid Media — 8; 12 Weeks — p=0.0546